Abstract
Brain-derived neurotrophic factor (BDNF) is a kind of small molecule basic protein mainly synthesized in cortical areas and widely expressed in central nervous system.According to recent studies, BDNF plays a role in protection, nutrition and anti-apoptosis to retinal cells, including retinal ganglion cells (RGCs), retinal photoreceptor cells (RPCs) and retinal pigment epithelium (RPE) cells.Retinitis pigmentosa (RP) is a degenerative fundus disease due to the progressive degeneration of the RPCs in the retina.Mammalian modules verified the value of long-term BDNF in RP therapy.However, short half-life in vivo and failing to pass the blood-retina barrier become the obstacles to deliver BDNF intraocular, which bring challenges to BDNF applying in clinic.To make BDNF release intraocular stable and sustained, novel delivery system for BDNF have been tasted, such as gene engineering techniques, cell plantation techniques, sustained-released polymer delivery system and eye-drops.This article focuses on current research status of BDNF to RP treatment and its novel drug delivery system. Key words: Brain-derived neurotrophic factor; Retinitis pigmentosa; Therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
